Elicit: TNF-Blockers: Infection and Cancer Risks
TNF-Blockers: Infection and Cancer Risks
Explore safety/mechanism links for TNF-blocker associated infections and malignancies
Abstract
TNF-blockers demonstrate mechanistically coherent infection risks linked to TNF’s essential role in immune surveillance and host defense. While overall infection risk shows only modest increases (OR 1.18-1.20) that become non-significant when adjusted for exposure time (IRR 1.01), opportunistic infections show consistent 90% increased risk (OR 1.90) and tuberculosis risk increases 3- to 4-fold (OR 3.3-3.5). The mechanism centers on disruption of granuloma formation, explaining why tuberculosis occurs exclusively with monoclonal antibodies that completely neutralize TNF and why 72% of infliximab-associated granulomatous infections occur within 90 days, consistent with reactivation of latent infections rather than increased susceptibility to new pathogens.
Agent-specific differences are substantial, with infliximab carrying 3.25-fold greater granulomatous infection risk than etanercept, reflecting mechanistic differences between complete TNF neutralization and partial receptor blockade.
For malignancies, competing biological mechanisms—TNF’s dual roles in suppressing tumors through apoptosis versus promoting cancer through chronic inflammation—generate heterogeneous findings that resolve upon careful examination. Long-term observational studies show no overall increased malignancy risk (OR 0.90-0.95) and no evidence that longer exposure increases risk, while short-term RCT meta-analyses finding elevated risk (OR 3.3) likely reflect detection bias given inadequate latency periods for cancer development. Skin cancers represent the most consistent signal (OR 1.45 for non-melanoma skin cancer), amplified by concomitant methotrexate (RR 1.97).
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question. More on methods
Records from Elicit search
n = 200
Papers screened using: TNF-Blocker Intervention, Safety or Mechanistic Outcomes, Study Design, Adult Population, Clinical Indication, TNF-Specific Focus, Adequate Sample Size, Original Human Clinical Data
n = 200
Papers screened out
n = 190
Papers included for extraction
n = 10
Data extraction
We asked a large language model to extract each data column below from each paper.
- TNF-Blocker Details: Extract comprehensive details about the TNF-blocker therapy studied.
- Patient Population: Extract details about the study population relevant to TNF-blocker safety.
- Infection Outcomes: Extract all infection-related safety outcomes for TNF-blockers.
- Malignancy Outcomes: Extract all malignancy-related safety outcomes for TNF-blockers.
- Mechanistic Insights: Extract any discussion of biological mechanisms linking TNF-blockers to infections or malignancies.
- Risk Factors: Extract patient or treatment factors that modify infection or malignancy risk with TNF-blockers.
- Study Methodology: Extract study design features relevant to interpreting TNF-blocker safety data.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study design | Patient population | Sample size (treatment/control) | TNF-blockers studied | Follow-up duration |
|---|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | Yes | Systematic review and meta-analysis of RCTs | Plaque psoriasis and psoriatic arthritis | 4,598/2,313 | Etanercept, infliximab, adalimumab, golimumab, certolizumab | Mean 17.8 weeks (range 12-30 weeks) |
| S. Minozzi et al., 2016 | Yes | Systematic review and meta-analysis of RCTs and open-label extension studies | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis | 14,766/7,994 | Adalimumab, golimumab, infliximab, certolizumab, etanercept | 1-36 months (RCTs), 6-48 months (open-label extensions) |
| M. Muller et al., 2020 | No | Systematic review of observational cohort studies | Inflammatory bowel disease | 298,717 (no control group) | Infliximab, adalimumab | Mean 7-80 months |
| Sean M. McConachie et al., 2018 | No | Systematic review of meta-analyses and cohort studies | Inflammatory bowel disease | Not mentioned | Infliximab, adalimumab, certolizumab, golimumab | Not mentioned |
| R. Pereira et al., 2017 | No | Observational cohort study | Immune-mediated inflammatory diseases | Not mentioned | Not specified | January 2000-December 2014 |
| T. Bongartz et al., 2006 | No | Meta-analysis of RCTs | Rheumatoid arthritis | 3,493/1,512 | Infliximab, adalimumab | At least 12 weeks |
| X. Mariette et al., 2011 | No | Systematic review and meta-analysis of observational studies | Rheumatoid arthritis | Not mentioned | Not specified | Not mentioned |
| D. Solomon et al., 2012 | Yes | Systematic review of observational cohort studies | Rheumatoid arthritis | Not specified | Infliximab, adalimumab, etanercept | Relatively short duration |
| S. Bonovas et al., 2016 | Yes | Systematic review and meta-analysis of RCTs | Inflammatory bowel disease | 9,003/5,587 | Adalimumab, certolizumab, golimumab, infliximab, natalizumab, vedolizumab | 1-24 months, average 6.5 months |
| R. Wallis et al., 2004 | No | Registry-based study using FDA Adverse Event Reporting System | Not specified | Not mentioned | Infliximab, etanercept | January 1998-September 2002 |
Infection Outcomes
| Study | Any infection | Serious infections | Opportunistic infections | Tuberculosis | Other notable findings |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.18 (95% CI 1.05-1.33) IRR 1.01 (95% CI 0.92-1.11) |
OR 0.70 (95% CI 0.40-1.21) IRR 0.59 (95% CI 0.35-0.99) |
Not measured | Not measured | Most common site: cellulitis |
| S. Minozzi et al., 2016 | OR 1.20 (95% CI 1.08-1.34) | OR 1.41 (95% CI 1.16-1.73) fixed effects OR 1.25 (95% CI 1.01-1.55) random effects |
OR 0.94 (95% CI 0.33-2.64) fixed effects OR 0.81 (95% CI 0.23-2.87) random effects |
OR 3.53 (95% CI 1.58-7.85) fixed effects OR 3.29 (95% CI 1.48-7.33) random effects |
Risk increased with longer treatment duration |
| M. Muller et al., 2020 | Not reported | Not reported | Not reported | Not reported | Focus on malignancy outcomes |
| Sean M. McConachie et al., 2018 | Meta-analyses showed inconclusive association | Not specified | Registry data suggest independent risk | Not specified | Risk factors: older age, malnutrition, diabetes, combination therapy |
| R. Pereira et al., 2017 | Not reported | IR 4.02/100 patient-years (95% CI 3.20-5.04) | Not reported | IR 0.28/100 patient-years (95% CI 0.12-0.66) 60% extrapulmonary |
Most frequent site: gastrointestinal system TB exclusively with monoclonal antibodies |
| T. Bongartz et al., 2006 | Not reported | OR 2.0 (95% CI 1.3-3.1) NNH 59 (95% CI 39-125) for 3-12 months |
Not reported | Not reported | Not specified |
| X. Mariette et al., 2011 | Not reported | Not reported | Not reported | Not reported | Study focused on malignancy outcomes |
| D. Solomon et al., 2012 | Not reported | Not reported | Not reported | Not reported | Study focused on malignancy outcomes |
| S. Bonovas et al., 2016 | OR 1.19 (95% CI 1.10-1.29) NNH 26 |
OR 0.89 (95% CI 0.71-1.12) OR 0.56 (95% CI 0.35-0.90) in low-risk bias studies |
OR 1.90 (95% CI 1.21-3.01) NNH 194 |
OR 2.04 (95% CI 0.71-5.89) | Specific pathogens: M. tuberculosis, JC virus, Nocardia, CMV/EBV, candidiasis, VZV, P. jirovecii, H. capsulatum |
| R. Wallis et al., 2004 | Not reported | Not reported | 239/100,000 for infliximab vs 74/100,000 for etanercept | 144/100,000 for infliximab vs 35/100,000 for etanercept | 3.25-fold greater risk with infliximab vs etanercept 72% of infections within 90 days for infliximab |
Malignancy Outcomes
| Study | All-site malignancy | Non-melanoma skin cancer | Melanoma | Lymphoma | Other solid tumors |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.48 (95% CI 0.71-3.09) IRR 0.99 (95% CI 0.51-1.90) |
OR 1.33 (95% CI 0.58-3.04) 70.6% of all malignancies |
Not separately analyzed | OR 1.26 (95% CI 0.39-4.15) when NMSC excluded | Prostate and breast cancer reported |
| M. Muller et al., 2020 | 1.0% overall occurrence No significant association in 10/11 studies |
123/692 cases (17.8%) | Not specified | 106/692 cases (15.3%) One study found increased risk |
Digestive malignancies: 120/692 (17.3%) |
| R. Pereira et al., 2017 | IR 1.75/100 patient-years (95% CI 1.24-2.47) | Not specified | Not specified | Not specified | Not specified |
| T. Bongartz et al., 2006 | OR 3.3 (95% CI 1.2-9.1) NNH 154 (95% CI 91-500) for 6-12 months |
Not separately analyzed | Not separately analyzed | Not separately analyzed | Dose-dependent relationship observed |
| X. Mariette et al., 2011 | OR 0.95 (95% CI 0.85-1.05) | OR 1.45 (95% CI 1.15-1.76) | OR 1.79 (95% CI 0.92-2.67) | OR 1.11 (95% CI 0.70-1.51) | No evidence longer exposure increases risk |
| D. Solomon et al., 2012 | Various estimates from different studies | OR 1.24 (95% CI 0.97-1.58) alone RR 1.97 (95% CI 1.51-2.58) with MTX |
Not specified | Risk estimates ranged 1.1-4.9 SIR 1.8-6.0 among TNFi users |
Hematologic malignancies SIR 2.0-4.1 |
| S. Bonovas et al., 2016 | OR 0.90 (95% CI 0.54-1.50) 0.45% treatment vs 0.54% placebo |
Not separately analyzed | Not separately analyzed | Not separately analyzed | Insufficient data on exposure/follow-up |
Mechanistic Insights
TNF plays a critical role in immune surveillance and host defense, creating a theoretical framework for both infection and malignancy risks with TNF inhibition. Multiple biological pathways have been proposed to explain the observed safety signals.
For infections, TNF-α antagonists suppress inflammatory pathways that are essential for immune defense. The disruption of granuloma formation represents a key mechanism for tuberculosis reactivation, as granulomas are crucial for containing mycobacterial infections. This mechanistic understanding explains why tuberculosis risk is elevated 3- to 4-fold and why TB occurs exclusively with monoclonal antibodies that more completely neutralize TNF, compared to the soluble receptor etanercept which may have different immunologic effects.
The clustering of granulomatous infections within 90 days of infliximab initiation is consistent with reactivation of latent infections, suggesting that TNF-blockade unmasks pre-existing but controlled pathogens rather than solely increasing susceptibility to new infections. This mechanistic insight has important implications for pre-treatment screening protocols.
For malignancies, competing mechanisms have been proposed. TNF may suppress tumor development through induction of apoptosis and suppressive effects on gene expression, suggesting that TNF-blockade could enhance cancer risk. Additionally, TNF serves as a key element of inflammatory responses whose inhibition may increase risk of infection-driven cancers, particularly viral malignancies.
Conversely, uncontrolled inflammation itself may potentiate cancer development, as evidenced by higher lymphoma rates in patients with greater systemic inflammation. TNF’s profound effects on angiogenesis, which is critical for tumor growth and metastasis, suggest that anti-TNF therapy could theoretically reduce cancer risk by suppressing both inflammation and angiogenesis.
When TNF-blockers are combined with other immunosuppressants, synergistic immunosuppression may increase both infection and malignancy risks. This is particularly evident for non-melanoma skin cancers, where the combination of TNF-blockers with methotrexate nearly doubled the risk compared to TNF-blockers alone.
Risk Factors and Population Heterogeneity
Several patient and treatment characteristics modified infection and malignancy risk. Older age emerged as a risk factor for infections, though one meta-regression found no significant age association. Comorbid conditions including malnutrition and diabetes increased infection susceptibility.
Concomitant immunosuppressive therapy represented an important modifier, with evidence of synergistic effects when combining TNF-blockers with other systemic immunosuppressants.
Disease-specific factors showed variable effects. For infections, Crohn’s disease patients demonstrated higher opportunistic infection risk compared to ulcerative colitis. The gastrointestinal system was the most frequent site of serious infections, potentially reflecting the intestinal inflammation in IBD populations.
Treatment-related factors included dose-dependent relationships for malignancies and duration-dependent increases in infection risk. However, longer TNF-blocker exposure did not increase malignancy risk in observational cohorts.
Agent-specific differences were notable. Infliximab carried 3.25-fold greater granulomatous infection risk than etanercept, with tuberculosis occurring exclusively with monoclonal antibodies. This suggests that complete TNF neutralization by monoclonal antibodies may have different immunologic consequences than the partial blockade achieved by the soluble receptor etanercept.
Synthesis
The systematic review data reveal a complex safety profile for TNF-blockers that cannot be reduced to simple risk estimates. The apparent contradictions in findings can be reconciled by considering methodological factors, population characteristics, and temporal dynamics.
For serious infections, the divergence between meta-analyses finding increased risk (OR 1.25-2.0) and those finding no increase or even protective effects reflects differences in study quality and outcome ascertainment. The consistent signal for opportunistic infections (OR 1.90) and tuberculosis (OR 3.3-3.5) represents a mechanistically plausible effect.
For malignancies, the heterogeneity is even more pronounced, with estimates ranging from protective to substantially increased risk (OR 3.3). This variance can be explained by study duration, malignancy type specificity, population-specific baseline risk, dose-response relationships, and agent-specific effects.
In summary, TNF-blockers demonstrate a mechanistically coherent increased risk of opportunistic infections, particularly tuberculosis reactivation, that appears to be agent-specific and related to granuloma disruption. For malignancies, the preponderance of evidence from longer-term observational studies suggests no overall increased risk, though skin cancers may be modestly increased, particularly with combination immunosuppression.